Association between perioperative crystalloid infusion management and changes in total body water, extracellular water, hemodynamics, catecholamine dependency, function of Glykokalyx and associated homonal/metabolic signals --- a pilot study

Conditions: I25.9
Chronic ischaemic heart disease, unspecified

Registration Number: DRKS00011694

Lead Sponsor: Klinik für Anästhesiologie und IntensivmedizinUniversitätsklinikum Jena

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 26

Inclusion Criteria

Elective cardiac srugery -- OPCAB only
Age > 18 years
Written informed consent
Patients with or without type-2 diabetes and micro-/ macro-Albuminurea

Exclusion Criteria

Study withdrawal
Recruitment in other clinical trial
Personel of Jena university hospital or relatives
Patients undergoing surgery with cardiopulmonary bypass

Study & Design

Study Type: observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Study Endpoint: To analyze the effect of crystalloid fluid infusion on total body water and composition of the extracellular and intracellular space defined by central and peripheral edema. Catecholamine dependency and renal dysfunction will also be assessed.<br><br>Measurement:<br>- Bioimpedance Analysis to evaluate body water composition<br>- blood samples to measure Glycocalyx<br>- Lung ultrasound to measure central edema<br>- skin wrinkels to measure peripheral edema<br>- Hemodynamics with Pulse contour cardiac output <br><br>Timepoint of measurement:<br>- prior anaesthesia<br>- immediately after surgery<br>- on postoperative days 1 and 2<br>- prior discharge from Intensive care unit<br>- prior hospital discharge<br>

Secondary Outcome Measures

Name	Time	Method
1. Association of total body fluid, hemodynamic and lung water content in the perioperative period<br>2. Measurement of Gykokalyxdysfunction<br>3. Expression of hormonactive peptides in the epicardial adipose tissue and blood plasma<br>4. Metabolomics in epicardial adipose tissue<br>5. To evaluate differences between patients with type-2 diabetes and patients without diabetes<br>6 To monitor the clinical outcome